

Amendment to NarcLO-FDHA from 1 March 2023

On 1 March 2023, tramadol will be incorporated in List B, Annex 3 NarcLO-FDHA (SR 812.121.11):

Tramadol

Ready-to-use medicinal products are not subject to control. Companies with an establishment licence for handling controlled substances from List B are not subject to control for manufacturing and their own subsequent trading in Switzerland or export.

This means:

Ready-to-use medicinal products:

Ready-to-use medicinal products containing tramadol are not subject to control. There is no change for these medicinal products.

Manufacturing establishments with an establishment licence for handling controlled substances from List B:

Manufacturing and associated activities for these establishments are not subject to control. This includes the actual manufacture of active pharmaceutical ingredients (APIs), intermediates or preparations and the relevant analytics and storage. Trading in Switzerland and export of the goods manufactured by the authorised company (API, intermediate or preparation) are also not subject to control.

All other cases:

Handling of tramadol is subject to control measures, with the exception of ready-to-use medicinal products. This also applies to trading in Switzerland and abroad by companies that do not manufacture tramadol themselves or use it in manufacturing.